WO2021231476A1 - Glutathione trisulfide (gsssg) in neuroprotection - Google Patents

Glutathione trisulfide (gsssg) in neuroprotection Download PDF

Info

Publication number
WO2021231476A1
WO2021231476A1 PCT/US2021/031842 US2021031842W WO2021231476A1 WO 2021231476 A1 WO2021231476 A1 WO 2021231476A1 US 2021031842 W US2021031842 W US 2021031842W WO 2021231476 A1 WO2021231476 A1 WO 2021231476A1
Authority
WO
WIPO (PCT)
Prior art keywords
gsssg
composition
effective amount
administering
thoracic
Prior art date
Application number
PCT/US2021/031842
Other languages
French (fr)
Inventor
Fumito Ichinose
Eizo MARUTANI
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Priority to US17/924,622 priority Critical patent/US20230181676A1/en
Priority to BR112022022746A priority patent/BR112022022746A2/en
Priority to KR1020227042758A priority patent/KR20230009425A/en
Priority to CN202180045960.8A priority patent/CN115996941A/en
Priority to JP2022568697A priority patent/JP2023526221A/en
Priority to CA3182905A priority patent/CA3182905A1/en
Priority to EP21804146.5A priority patent/EP4149951A4/en
Publication of WO2021231476A1 publication Critical patent/WO2021231476A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic

Definitions

  • Glutathione Trisulfide (GSSSG) in Neuroprotection
  • GSSSG glutathione trisulfide
  • the methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.
  • ischemic spinal cord injury SCI
  • ischemic SCI ischemic spinal cord injury
  • the methods include administering a therapeutically or prophylactically effective amount of a composition prepared using crystals of Glutathione Trisulfide (GSSSG) to a subject in need thereof.
  • the methods include comprising preparing the composition comprising GSSSG by dissolving a crystalline form of GSSSG in saline at pH 3-6.
  • compositions comprising GSSSG for use in a method of treatment, or reduction of risk, of a disorder associated with neurodegeneration in a subject e.g., compositions prepared by dissolving a crystalline form of GSSSG in saline at pH 3-6. .
  • the disorder is post-ischemic neuronal death.
  • the disorder is a chronic cerebral degenerative disease, e.g., multi-infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia.
  • a chronic cerebral degenerative disease e.g., multi-infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia.
  • the methods include administering an effective amount of a composition comprising GSSSG within a few minutes to hours after a traumatic injury occurs.
  • the methods include administering an effective amount of a composition comprising GSSSG before a scheduled thoracic and/or abdominal aortic surgical procedure.
  • the methods include administering an effective amount of a composition comprising GSSSG hours to days before a scheduled thoracic and/or abdominal aortic surgical procedure.
  • the methods include administering an effective amount of a composition comprising GSSSG 2-24 hours, and/or 1, 2, 3, 4, 5, 6, and/or7 days before the scheduled thoracic and/or abdominal aortic surgical procedure.
  • FIGs. 1A-B are graphs showing BMS (A) and survival rate (B) of mice subjected to SCI after preconditioning with GSSSG or DMSO alone.
  • Persulfide (R-S-SH) and polysulfide (R-S-Sn-S-R) are molecules that contain sulfane sulfur which is a sulfur atom with six valence electrons but with no charge, and possess protective effects against oxidative stress (Akaike et al, 2017; Ida et al, 2014). These molecules can release FhS and, therefore, antioxidative or protective effects of these molecules seem to be mediated by both FhS and sulfane sulfur.
  • Glutathione trisulfide (GSSSG) is one of major polysulfide species in mammal tissues that consists of GSSG, a metabolite of glutathione, with an additional sulfane sulfur atom.
  • the current study examined the beneficial effects of the crystal GSSSG in neuroprotection, including against neurofunctional impairment after SCI in mice. Specifically, the effects of GSSSG preconditioning prior to SCI onset were examined. Patients often undergo aortic surgery after a certain period (e.g., 1 week) of diagnosis depending on conditions, providing an opportunity to use a treatment as described herein to reduce their risk of post-surgical complications. In addition, the results confirmed a protective effect of GSSSG against l-methyl-4-phenylpyridinium (MPP+)-induced neuronal (SH-SY5Y cell) death. MPP+-poisoning is an in vitro model of Parkinson's disease, demonstrating that the crystal GSSSG can be used in neurodegenerative disease as well.
  • MPP+-poisoning is an in vitro model of Parkinson's disease, demonstrating that the crystal GSSSG can be used in neurodegenerative disease as well.
  • the results herein demonstrated the beneficial capacity of GSSSG crystal in neuroprotection in vivo.
  • the present results showed the effects of GSSSG preconditioning on neurofunctional preservation after SCI; the drug can also be administered after onset of ischemia due to its antioxidative effects.
  • the methods described herein include methods for the treatment, or reduction of risk, of disorders associated with neurodegeneration in a subject, e.g., a mammalian subject, e.g., a human or non-human veterinary subject.
  • the disorder is post-ischemic neuronal death.
  • the disorder is a chronic cerebral degenerative disease (e.g., multi-infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia).
  • the methods include administering a therapeutically effective amount of a composition comprising a crystalline form of GSSSG as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment.
  • to “treat” means to ameliorate at least one symptom of the disorder associated with neurodegeneration.
  • the conditions that can be treated using a method described herein can be associated with loss of motor control, paralysis or paraplegia.
  • Administration of a therapeutically effective amount of a compound described herein can result in improved motor control, reduced paralysis or paraplegia.
  • the methods can result in a reduction in risk of developing loss of motor control, paralysis or paraplegia.
  • Subjects who are at risk of developing loss of motor control, paralysis or paraplegia can include those who have suffered a traumatic injury as well as those who are about to undergo thoracic and/or abdominal aortic surgery.
  • These methods can include administering an effective amount of a GSSSG composition as described herein within a few minutes to hours after a traumatic injury occurs, and/or before, e.g., hours to days before, a scheduled thoracic and/or abdominal aortic surgical procedure.
  • an “effective amount” is an amount sufficient to effect beneficial or desired results.
  • a therapeutic amount is one that achieves the desired therapeutic effect.
  • This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms.
  • An effective amount can be administered in one or more administrations, applications or dosages.
  • the compositions can be administered one from one or more times per day to one or more times per week; including once every other day.
  • the GSSSG is administered every day for at least 2, 3, 4, 5, 6, or 7 days prior to a scheduled thoracic and/or abdominal aortic surgical procedure.
  • treatment of a subject with a therapeutically effective amount of the therapeutic compounds described herein can include a single treatment or a series of treatments.
  • Dosage, toxicity and therapeutic efficacy of the therapeutic compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
  • Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
  • levels in plasma may be measured, for example, by high performance liquid chromatography.
  • compositions comprising GSSSG as an active ingredient, wherein the compositions are prepared using a crystalline form of GSSSG as described in EP 3560947, by dissolving the crystalline GSSSG in a buffer, e.g., saline, at pH 3-6.
  • a method for producing the crystal form of glutathione trisulfide dehydrate can comprise precipitating a crystal of glutathione trisulfide dihydrate in an aqueous solution in which glutathione trisulfide is dissolved, and collecting the precipitated crystal of glutathione trisulfide dihydrate.
  • compositions typically include a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
  • compositions are typically formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, administration.
  • solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
  • the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • the GSSSG can be provided in a kit in a crystalline form with a sterile buffer (e.g., saline) at pH 3-6 for use in dissolving the crystals to prepare a solution for injection.
  • a sterile buffer e.g., saline
  • SCI was induced by placing the first clip on the aortic arch between the left common carotid artery and the left subclavian artery and the second clip on the origin of the left subclavian artery.
  • the completeness of the occlusion was ascertained by an immediate and sustained loss of any detectable pulse pressure in the femoral artery pressure tracing.
  • the clips were removed, and the chest was closed in layers.
  • the arterial catheter was removed, incisions were closed, and animals were allowed to recover from anesthesia.
  • Temperature of erector spinae muscle was monitored and maintained at 37.5°C during whole surgery until recovery from anesthesia.
  • BMS Basso Mouse Scale
  • mice were subjected to preconditioning with GSSSG treatment before induction of SCI. Briefly, GSSSG was ground using an agate mortar, dispersed in DMSO using a sonication water bath and administrated at 200 mg/kg IP daily for 4 days. Control mice were given DMSO alone. Mice were subjected to SCI at 24h after the last administration of GSSSG or DMSO alone.
  • mice treated with DMSO alone exhibited paraplegia after SCI while preconditioning with GSSSG prevented motor functional deficit and paraplegia (Fig. 1 A).
  • Preconditioning with GSSSG did not change survival rate of mice after SCI (Fig. IB).
  • MPP+-poisoning is an in vitro model of Parkinson's disease.
  • SH-SY5Y cells were incubated with or without MPP+ (2 mM) in DMEM/F12 (20%FBS) with or without drugs at 37°C for 24h. Cell viability was measured using the crystal violet assay.
  • TLR Toll-like receptor
  • TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. Journal of neurochemistry 102, 37-50.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for the use of glutathione trisulfide (GSSSG) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.

Description

Glutathione Trisulfide (GSSSG) in Neuroprotection
CLAIM OF PRIORITY
This application claims the benefit of U.S. Provisional Patent Application Serial No. 63/023,686, filed on May 12, 2020. The entire contents of the foregoing are hereby incorporated by reference.
TECHNICAL FIELD
Described herein is the use of glutathione trisulfide (GSSSG) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.
BACKGROUND
Delayed paraplegia is a devastating complication of ischemic spinal cord injury (SCI), which can occur after thoracic and/or abdominal aortic surgery and trauma to the spinal cord. While the incidence of ischemic SCI is reported to be around 3%, more than 80% present with delayed onset of symptoms (Ullery et al., 2011). Although mechanisms of delayed paraplegia are incompletely understood, studies suggest critical roles of motor neuron apoptosis (Kakinohana et al., 2011) and recruitment of microglia and bone marrow- derived macrophages (BMDM) in ischemic stroke(Denes et al, 2008) and SCI (Bell et al., 2013; Donnelly et al., 2011; Kigerl et al., 2007).
SUMMARY
Provided herein are methods for the treatment, or reduction of risk, of a disorder associated with neurodegeneration in a subject. The methods include administering a therapeutically or prophylactically effective amount of a composition prepared using crystals of Glutathione Trisulfide (GSSSG) to a subject in need thereof. In some embodiments, the methods include comprising preparing the composition comprising GSSSG by dissolving a crystalline form of GSSSG in saline at pH 3-6. Also provided are compositions comprising GSSSG for use in a method of treatment, or reduction of risk, of a disorder associated with neurodegeneration in a subject, e.g., compositions prepared by dissolving a crystalline form of GSSSG in saline at pH 3-6. .
In some embodiments, the disorder is post-ischemic neuronal death.
In some embodiments, the disorder is a chronic cerebral degenerative disease, e.g., multi-infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia.
In some embodiments, the methods include administering an effective amount of a composition comprising GSSSG within a few minutes to hours after a traumatic injury occurs.
In some embodiments, the methods include administering an effective amount of a composition comprising GSSSG before a scheduled thoracic and/or abdominal aortic surgical procedure.
In some embodiments, the methods include administering an effective amount of a composition comprising GSSSG hours to days before a scheduled thoracic and/or abdominal aortic surgical procedure.
In some embodiments, the methods include administering an effective amount of a composition comprising GSSSG 2-24 hours, and/or 1, 2, 3, 4, 5, 6, and/or7 days before the scheduled thoracic and/or abdominal aortic surgical procedure.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting.
All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims. DESCRIPTION OF DRAWINGS
FIGs. 1A-B are graphs showing BMS (A) and survival rate (B) of mice subjected to SCI after preconditioning with GSSSG or DMSO alone.
FIG. 2 is a graph showing that polysulfide, but not Na2S, protected SH-SY5Y cells from MPP+-induced cell death. N=4 each. *, **, ***, ****p<0.05, 0.01, 0.001, 0.0001 vs. vehicle; P<0.01 Control vs. MPP+ in each treatment.
DETAILED DESCRIPTION
Persulfide (R-S-SH) and polysulfide (R-S-Sn-S-R) are molecules that contain sulfane sulfur which is a sulfur atom with six valence electrons but with no charge, and possess protective effects against oxidative stress (Akaike et al, 2017; Ida et al, 2014). These molecules can release FhS and, therefore, antioxidative or protective effects of these molecules seem to be mediated by both FhS and sulfane sulfur. Glutathione trisulfide (GSSSG) is one of major polysulfide species in mammal tissues that consists of GSSG, a metabolite of glutathione, with an additional sulfane sulfur atom.
Until recently, methods for manufacturing GSSG compounds included the use of toxic gases or risked the production of toxic gases, producing a compound that was not stable or not suitable for pharmaceutical use. EP 3560947 describes a method of manufacturing GSSSG in a stable crystal form. However, the efficacy of this crystal form of GSSSG in vivo for neuroprotection has not been described.
The current study examined the beneficial effects of the crystal GSSSG in neuroprotection, including against neurofunctional impairment after SCI in mice. Specifically, the effects of GSSSG preconditioning prior to SCI onset were examined. Patients often undergo aortic surgery after a certain period (e.g., 1 week) of diagnosis depending on conditions, providing an opportunity to use a treatment as described herein to reduce their risk of post-surgical complications. In addition, the results confirmed a protective effect of GSSSG against l-methyl-4-phenylpyridinium (MPP+)-induced neuronal (SH-SY5Y cell) death. MPP+-poisoning is an in vitro model of Parkinson's disease, demonstrating that the crystal GSSSG can be used in neurodegenerative disease as well. The results herein demonstrated the beneficial capacity of GSSSG crystal in neuroprotection in vivo. The present results showed the effects of GSSSG preconditioning on neurofunctional preservation after SCI; the drug can also be administered after onset of ischemia due to its antioxidative effects.
Methods of Treatment
The methods described herein include methods for the treatment, or reduction of risk, of disorders associated with neurodegeneration in a subject, e.g., a mammalian subject, e.g., a human or non-human veterinary subject. In some embodiments, the disorder is post-ischemic neuronal death. In some embodiments, the disorder is a chronic cerebral degenerative disease (e.g., multi-infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia). Generally, the methods include administering a therapeutically effective amount of a composition comprising a crystalline form of GSSSG as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment.
As used in this context, to “treat” means to ameliorate at least one symptom of the disorder associated with neurodegeneration. The conditions that can be treated using a method described herein can be associated with loss of motor control, paralysis or paraplegia. Administration of a therapeutically effective amount of a compound described herein can result in improved motor control, reduced paralysis or paraplegia.
In addition, the methods can result in a reduction in risk of developing loss of motor control, paralysis or paraplegia. Subjects who are at risk of developing loss of motor control, paralysis or paraplegia can include those who have suffered a traumatic injury as well as those who are about to undergo thoracic and/or abdominal aortic surgery. These methods can include administering an effective amount of a GSSSG composition as described herein within a few minutes to hours after a traumatic injury occurs, and/or before, e.g., hours to days before, a scheduled thoracic and/or abdominal aortic surgical procedure.
An “effective amount” is an amount sufficient to effect beneficial or desired results. For example, a therapeutic amount is one that achieves the desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms. An effective amount can be administered in one or more administrations, applications or dosages. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. In some embodiments, the GSSSG is administered every day for at least 2, 3, 4, 5, 6, or 7 days prior to a scheduled thoracic and/or abdominal aortic surgical procedure. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the therapeutic compounds described herein can include a single treatment or a series of treatments.
Dosage, toxicity and therapeutic efficacy of the therapeutic compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
Pharmaceutical Compositions and Methods of Administration
The methods described herein include the use of pharmaceutical compositions comprising GSSSG as an active ingredient, wherein the compositions are prepared using a crystalline form of GSSSG as described in EP 3560947, by dissolving the crystalline GSSSG in a buffer, e.g., saline, at pH 3-6. A method for producing the crystal form of glutathione trisulfide dehydrate can comprise precipitating a crystal of glutathione trisulfide dihydrate in an aqueous solution in which glutathione trisulfide is dissolved, and collecting the precipitated crystal of glutathione trisulfide dihydrate.
Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, administration.
Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY). For example, solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof. The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. For example, the GSSSG can be provided in a kit in a crystalline form with a sterile buffer (e.g., saline) at pH 3-6 for use in dissolving the crystals to prepare a solution for injection.
EXAMPLES
The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
Example 1. Preventive effects of GSSSG against neurofunctional deficit after
SCI
To elucidate the molecular mechanisms responsible for the delayed paraplegia, we recently developed and thoroughly characterized a murine model of SCI in which mice exhibit delayed paraplegia with minimum operative mortality (Kakinohana et al.,
2011). Briefly, under anesthesia and mechanical ventilation via endotracheal intubation, SCI was induced by placing the first clip on the aortic arch between the left common carotid artery and the left subclavian artery and the second clip on the origin of the left subclavian artery. The completeness of the occlusion was ascertained by an immediate and sustained loss of any detectable pulse pressure in the femoral artery pressure tracing. After 5 min of ischemia, the clips were removed, and the chest was closed in layers. At 10 minutes of reperfusion, the arterial catheter was removed, incisions were closed, and animals were allowed to recover from anesthesia. Temperature of erector spinae muscle was monitored and maintained at 37.5°C during whole surgery until recovery from anesthesia. In sham-operated mice, whole surgical procedure was performed as described, but no clips were applied. Motor function was quantified serially at pre-SCI, 24, 48, and 72 h after spinal cord ischemia by the Basso Mouse Scale (BMS) (Basso et al, 2006; Kakinohana et al, 2011). The maximum deficit is indicated by a score of 0. Although BMS score <6 (0 to 5) indicates paraplegia, BMS score >6 (6 to 9) indicates ability to walk.
To examine preventive effects of GSSSG against neurofunctional deficit after SCI, mice were subjected to preconditioning with GSSSG treatment before induction of SCI. Briefly, GSSSG was ground using an agate mortar, dispersed in DMSO using a sonication water bath and administrated at 200 mg/kg IP daily for 4 days. Control mice were given DMSO alone. Mice were subjected to SCI at 24h after the last administration of GSSSG or DMSO alone.
The results showed that all mice treated with DMSO alone exhibited paraplegia after SCI while preconditioning with GSSSG prevented motor functional deficit and paraplegia (Fig. 1 A). Preconditioning with GSSSG did not change survival rate of mice after SCI (Fig. IB).
Example 2. Protective effects of GSSSG in a model of neurodegeneration
The effects of GSSSG on l-methyl-4-phenylpyridinium (MPP+)-induced neuronal (SH-SY5Y cell) death were evaluated. MPP+-poisoning is an in vitro model of Parkinson's disease.
SH-SY5Y cells were incubated with or without MPP+ (2 mM) in DMEM/F12 (20%FBS) with or without drugs at 37°C for 24h. Cell viability was measured using the crystal violet assay.
The results, shown in Fig. 2, demonstrated that polysulfide, but not Na2S, protected SH-SY5Y cells from MPP+-induced cell death.
References Cited
Akaike, T., Ida, T., Wei, F.-Y., Nishida, M., Kumagai, Y., Alam, M.M., Ihara, FL, Sawa, T., Matsunaga, T., Kasamatsu, S., et al. (2017). Cysteinyl-tRNA synthetase governs cysteine polysulfidation and mitochondrial bioenergetics. Nature Communications 8, 1177-1177.
Basso, D.M., Fisher, L.C., Anderson, A.J., Jakeman, L.B., McTigue, D.M., and Popovich, P.G. (2006). Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 23, 635-659.
Bell, M.T., Puskas, F., Agoston, V.A., Cleveland, J.C., Freeman, K.A., Gamboni, F., Herson, P.S., Meng, X., Smith, P.D., Weyant, M.J., et al. (2013). Toll-Like Receptor 4-Dependent Microglial Activation Mediates Spinal Cord Ischemia-Reperfusion Injury. Circulation 128, S152-S156. Denes, A., Ferenczi, S., Halasz, I, Kornyei, Z., and Kovacs, K.J. (2008). Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 28, 1707-1721.
Donnelly, D.J., Longbrake, E.E., Shawler, T.M., Kigerl, K.A., Lai, W., Tovar, C.A., Ransohoff, R.M., and Popovich, P.G. (2011). Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. The Journal of neuroscience : the official journal of the Society for Neuroscience 31, 9910-9922.
Ida, T., Sawa, T., Ihara, FL, Tsuchiya, Y., Watanabe, Y., Kumagai, Y., Suematsu, M, Motohashi, FL, Fujii, S., Matsunaga, T., et al. (2014). Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proceedings of the National Academy of Sciences.
Kakinohana, M., Kida, K., Minamishima, S., Atochin, D.N., Huang, P.L., Kaneki, M., and Ichinose, F. (2011). Delayed Paraplegia After Spinal Cord Ischemic Injury Requires Caspase-3 Activation in Mice. Stroke.
Kigerl, K.A., Lai, W., Rivest, S., Hart, R.P., Satoskar, A.R, and Popovich, P.G. (2007). Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. Journal of neurochemistry 102, 37-50.
Ullery, B.W., Cheung, A.T., McGarvey, M.L., Jackson, B.M., and Wang, G.J. (2011). Reversal of delayed-onset paraparesis after revision thoracic endovascular aortic repair for ruptured thoracic aortic aneurysm. Ann Vase Surg 25, 840 e819-823.
OTHER EMBODIMENTS
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A method for the treatment, or reduction of risk, of a disorder associated with neurodegeneration in a subject, the method comprising administering a therapeutically or prophylactically effective amount of a composition prepared using crystals of Glutathione Trisulfide (GSSSG) to a subject in need thereof.
2. The method of claim 1, further comprising preparing the composition comprising GSSSG by dissolving a crystalline form of GSSSG in saline at pH 3-6.
3. The method of claim 1, wherein the disorder is post-ischemic neuronal death.
4. The method of claim 1, wherein the disorder is a chronic cerebral degenerative disease.
5. The method of claim 1, wherein the chronic cerebral degenerative disease is multi infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia.
6. The method of claim 1, comprising administering an effective amount of a composition comprising GSSSG within a few minutes to hours after a traumatic injury occurs.
7. The method of claim 1, comprising administering an effective amount of a composition comprising GSSSG before a scheduled thoracic and/or abdominal aortic surgical procedure.
8. The method of claim 7, comprising administering an effective amount of a composition comprising GSSSG hours to days before a scheduled thoracic and/or abdominal aortic surgical procedure.
9. The method of claim 8, comprising administering an effective amount of a composition comprising GSSSG 2-24 hours, and/or 1, 2, 3, 4, 5, 6, and/or7 days before the scheduled thoracic and/or abdominal aortic surgical procedure.
10. A composition prepared using crystals of Glutathione Trisulfide (GSSSG) for use in the treatment, or reduction of risk, of a disorder associated with neurodegeneration in a subject, the method comprising administering a therapeutically or prophy tactically effective amount of to a subject in need thereof.
11. The composition for the use of claim 10, wherein the composition is prepared by a method comprising dissolving a crystalline form of GSSSG in saline at pH 3-6.
12. The composition for the use of claim 10, wherein the disorder is post-ischemic neuronal death.
13. The composition for the use of claim 10, wherein the disorder is a chronic cerebral degenerative disease.
14. The composition for the use of claim 10, wherein the chronic cerebral degenerative disease is multi-infarct dementia, Alzheimer’s disease, Parkinson’s disease, or Lewy body dementia.
15. The composition for the use of claim 10, wherein the method comprises administering an effective amount of a composition comprising GSSSG within a few minutes to hours after a traumatic injury occurs.
16. The composition for the use of claim 10, wherein the method comprises administering an effective amount of a composition comprising GSSSG before a scheduled thoracic and/or abdominal aortic surgical procedure.
17. The composition for the use of claim 16, wherein the method comprises administering an effective amount of a composition comprising GSSSG hours to days before a scheduled thoracic and/or abdominal aortic surgical procedure.
18. The composition for the use of claim 17, wherein the method comprises administering an effective amount of a composition comprising GSSSG 2-24 hours, and/or 1, 2, 3, 4, 5, 6, and/or7 days before the scheduled thoracic and/or abdominal aortic surgical procedure.
PCT/US2021/031842 2020-05-12 2021-05-11 Glutathione trisulfide (gsssg) in neuroprotection WO2021231476A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US17/924,622 US20230181676A1 (en) 2020-05-12 2021-05-11 Glutathione trisulfide (gsssg) in neuroprotection
BR112022022746A BR112022022746A2 (en) 2020-05-12 2021-05-11 GLUTATHIONE TRISULPHIDE (GSSSG) IN NEUROPROTECTION
KR1020227042758A KR20230009425A (en) 2020-05-12 2021-05-11 Glutathione trisulfide (GSSSG) in neuroprotection
CN202180045960.8A CN115996941A (en) 2020-05-12 2021-05-11 Glutathione trisulfide (GSSSG) in neuroprotection
JP2022568697A JP2023526221A (en) 2020-05-12 2021-05-11 Glutathione Trisulfide (GSSSG) in Neuroprotection
CA3182905A CA3182905A1 (en) 2020-05-12 2021-05-11 Glutathione trisulfide (gsssg) in neuroprotection
EP21804146.5A EP4149951A4 (en) 2020-05-12 2021-05-11 Glutathione trisulfide (gsssg) in neuroprotection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023686P 2020-05-12 2020-05-12
US63/023,686 2020-05-12

Publications (1)

Publication Number Publication Date
WO2021231476A1 true WO2021231476A1 (en) 2021-11-18

Family

ID=78524941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/031842 WO2021231476A1 (en) 2020-05-12 2021-05-11 Glutathione trisulfide (gsssg) in neuroprotection

Country Status (8)

Country Link
US (1) US20230181676A1 (en)
EP (1) EP4149951A4 (en)
JP (1) JP2023526221A (en)
KR (1) KR20230009425A (en)
CN (1) CN115996941A (en)
BR (1) BR112022022746A2 (en)
CA (1) CA3182905A1 (en)
WO (1) WO2021231476A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023282269A1 (en) * 2021-07-08 2023-01-12 協和ファーマケミカル株式会社 Prophylactic or therapeutic drug for parkinson's disease
WO2023038088A1 (en) * 2021-09-09 2023-03-16 国立大学法人九州大学 Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound
WO2023225305A3 (en) * 2022-05-20 2024-02-22 The General Hospital Corporation Intranasal administration of polysulfide
WO2024048479A1 (en) * 2022-08-30 2024-03-07 国立大学法人東北大学 Ischemia-reperfusion injury inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252897A1 (en) * 2007-06-25 2013-09-26 Fred Hutchinson Cancer Research Center Methods and Compositions Regarding Polychalcogenide Compositions
US20200079818A1 (en) * 2016-12-20 2020-03-12 Kyowa Hakko Bio Co., Ltd. Crystal of glutathione trisulfide dihydrate and method for producing same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225305A2 (en) * 2022-05-20 2023-11-23 The General Hospital Corporation Intranasal administration of polysulfide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252897A1 (en) * 2007-06-25 2013-09-26 Fred Hutchinson Cancer Research Center Methods and Compositions Regarding Polychalcogenide Compositions
US20200079818A1 (en) * 2016-12-20 2020-03-12 Kyowa Hakko Bio Co., Ltd. Crystal of glutathione trisulfide dihydrate and method for producing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHA ET AL.: "Protein Glutathionylation in the Pathogenesis of Neurodegenerative Diseases", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2017, pages 1 - 9, XP055705286, DOI: 10.1155/2017/2818565 *
See also references of EP4149951A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023282269A1 (en) * 2021-07-08 2023-01-12 協和ファーマケミカル株式会社 Prophylactic or therapeutic drug for parkinson's disease
WO2023038088A1 (en) * 2021-09-09 2023-03-16 国立大学法人九州大学 Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound
WO2023225305A3 (en) * 2022-05-20 2024-02-22 The General Hospital Corporation Intranasal administration of polysulfide
WO2024048479A1 (en) * 2022-08-30 2024-03-07 国立大学法人東北大学 Ischemia-reperfusion injury inhibitor

Also Published As

Publication number Publication date
BR112022022746A2 (en) 2023-01-31
CN115996941A (en) 2023-04-21
KR20230009425A (en) 2023-01-17
CA3182905A1 (en) 2021-11-18
JP2023526221A (en) 2023-06-21
EP4149951A1 (en) 2023-03-22
US20230181676A1 (en) 2023-06-15
EP4149951A4 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US20230181676A1 (en) Glutathione trisulfide (gsssg) in neuroprotection
Sánchez-Aguilar et al. Effect of rosuvastatin on cytokines after traumatic head injury
Sangobowale et al. Minocycline plus N-acetylcysteine reduce behavioral deficits and improve histology with a clinically useful time window
EP2635269B1 (en) A combination composition
Wang et al. Cardioprotective effect of breviscapine: inhibition of apoptosis in H9c2 cardiomyocytes via the PI3K/Akt/eNOS pathway following simulated ischemia/reperfusion injury
KR20180100309A (en) Methods for the treatment of accumulated fats using deoxycholic acid and its salts
Dassanayake et al. Safety of subcutaneous adrenaline as prophylaxis against acute adverse reactions to anti-venom serum in snakebite
KR20170095926A (en) Sulfonamide pharmaceutical composition
Zhu et al. Shikonin regulates autophagy via the AMPK/mTOR pathway and reduces apoptosis of human umbilical cord mesenchymal stem cells to improve survival in tissues surrounding brain contusion
Hamed Cerebrolysin as a nerve growth factor for treatment of acquired peripheral nervous system diseases☆
Yim et al. A clinical study of Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of treatment in burn intensive care unit
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
EA029157B1 (en) Baclofen and acamprosate based therapy of macular degeneration
Goyal et al. Ivermectin-induced acute psychosis in patients infected with COVID-19 pneumonia
RU2493841C1 (en) Synergetic preparation for treating cardiovascular diseases, diabetes mellitus and hepatobiliary diseases
US20110009352A1 (en) Restorative agent for antibacterial peptide production ability
US7846901B2 (en) Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P
EP1121929A1 (en) Drug preparation &#34;histochrome&#34; for treating ocular conditions
JP2005538098A (en) Use of rain in therapeutic treatments that require elevated heme oxygenase levels
JP2900580B2 (en) Reactive oxygen disorder protective agent
JP6153838B2 (en) Vascular permeability inhibitor
CA3032858A1 (en) Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity
US6337322B1 (en) Preventives and remedies for intestinal mucosal disorder
Tazawa et al. Familial cholestasis with gallstone, ataxia and visual disturbance
CN109550041B (en) Application of oritavancin phosphate in preparation of medicine for preventing and treating infectious bovine rhinotracheitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21804146

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3182905

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022568697

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022022746

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227042758

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021804146

Country of ref document: EP

Effective date: 20221212

ENP Entry into the national phase

Ref document number: 112022022746

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221108